Upload
leon-ellis
View
215
Download
1
Tags:
Embed Size (px)
Citation preview
Pg 2
Ontario’s Evidence Revolution Commitment to Evidence in Healthcare
Ontario Excellent Care for All Act (2010)
The people of Ontario and their Government: Will ensure that healthcare providers are supported to plan for and improve the
quality of care they deliver based on the best available scientific evidence. (HQO formed to promulgate quality-based evidence)
Drummond Report (2012) (Healthcare) Policies should be based on evidence that provides guidance on
what services, procedures, devices and drugs are effective, efficient and eligible for public funding
Ontario Government Budget (2012) Evidence will drive decisions on funding new and existing procedures. The
government is committed to funding only those services that are supported by medical evidence.
The government will accelerate the evidence-based approach to care by building on the mandate of Health Quality Ontario (HQO)
Pg 3
Post-market assessment of technology performance in the real world through primary data gathering
Improves decision making prior to long-term commitment through appropriate adoption
Designed to inform policy and funded by government
Alternative is passive diffusion and intuitive decision making
Completed 19 and 19 ongoing. Ten CEDs significantly impacted policy decision making and published in peer reviewed journals
3
Dealing with Uncertainty – Field Evaluation Studies
Pg 4
Barriers to Adoption
Poor pre-market quality clinical trial
produces uncertaintyo Accuracy versus clinical utility for diagnostic tests
o No prospective economic analysis
o Research failed to address health system perspectives
o Me-too technologies
o Lack of generalisability
o Inadequate trial design e.g. randomization,
concealment, ITT – leading to low quality evidence
Policy including non-affordability,
competing pressures
Evidence used to police adoption in
Isolation from innovators
Pg 5
Health Technology Lifecycle in Ontario
Device Development
Pre-clinical- Design- Prototyping- Effectiveness
and safety testing in models
Device Manufacture and Testing
Clinical- Effectiveness
and safety testing in patients or using patient samples
Device Licensing
Government licensing- Application to
Health Canada for Licenses approving sale/use
PRE-MARKET
Patients have access to the device
Marketing, sales, distribution, education, training
POST-MARKET
Pg 6
Investment Regulation
Life-Cycle Diffusion Curve (Pre-Market Evidence Based Analysis)
1
TIME
Diffusion
Unconditional Yes
UncertaintyR&D
Unconditional No
Obsolescence
HORIZON
DEVELOP
TEST
UPre-Market Post-Market
Systematic review
Cost-Effectiveness (CE)
Effectiveness
• Efficacy Safety
• Value (CE) Affordability
• Ethical & societal
• Post market conditions
Systematic review
Cost-Effectiveness (CE)
E ff e c ti v e n e s s
Pg 7Pg 7
Milestone accomplishments Since December 2011, 20 companies have applied to EXCITE over 3 rounds.
10 technologies from innovative companies have been selected from a
tournament process and are proceeding:• The first round/pilot projects have gone through the full intake process,
consultation & proposal/budget generation, and contract execution. Currently recruiting the first patients into the clinical studies.
• The second round has completed review, consultation, and proposal generation. They are now in contract negotiations.
• The third round are in consultation and proposal generation.
• The fourth round applications are due October 7, 2013.
On May 30th, Minister Matthews announced EXCITE’s pilot participants:• ApneaDx – Home Sleep Apnea diagnosis
• Medtronic of Canada Ltd. – Symplicity Renal Denervation for hypertension
• Rna Diagnostics – Rna Disruption Assay (RDA) for early prediction of complete response to chemotherapy in breast cancer
EXCITE works with home-grown innovators from across Ontario while also attracting multinationals to conduct critical R&D in Ontario
• Applicants must submit an executive summary and all relevant reports, articles and materials related to the technology
• Health technologies are prioritized for participation in EXCITE based on the following criteria:o Relevance to the needs of the health systemo Disruptive potential (i.e., the promise of substantially better
clinical outcomes, including safety, and/or substantially lower system costs than existing approaches)
o Opportunities to identify obsolescence for existing alternative technologies
o Estimated magnitude of effect for the target populationo The stage of readiness of the technology and how effectively it
can be evaluatedo Potential benefit to Ontario, Canada (if relevant)
EXCITE selection criteria
Pg 11
• Acceptance of the invitation is made by way of a $10,000 fee to EXCITE, which is transferred in full to the Methodological Center (MC) to cover costs of developing the evaluation protocols • For SMEs, the amount is $5000 from SMEs, which is then
matched by EXCITE for transfer of $10,000 to the MC.
Consultation/protocol development
Pg 13
• The company is matched with a suitable MC, who is tasked with developing a proposal/protocol to meet the evaluation needs of the technology.
• Iterative process in consultation with the company• Typically takes 8-10 weeks
• The proposal contains a detailed overview of the proposed evaluation + robust budget for consideration
Pg 14
Specialized Methodological Centres & 24 Research Hospitals across the province.
METHODS CENTRE
METHODOLOGICAL CENTRES
Pg 15Pg 15
• Assess usability/human factors• Develop education system for training
end users• Investigate patient preferences• Analyze factors influencing of uptake• Develop a registry for tracking post-
adoption effectiveness + long-terms safety
• Knowledge transfer
• Safety + Effectiveness• Systematic Review• Economic Analysis
Core Evidentiary Bundle: Optional Additional Analyses:
15
EXCITE offers comprehensive analysis packages
• Acceptance of the proposal is made by way of signed agreements
The Evaluation
Pg 17
• The duration and cost of evaluations varies based on the complexity of the technology and the investigational testing protocol, including the sample size required
• Evaluations typically require 12-30 months to complete and cost $1-3 million
• EXCITE and the methodological centre report back regularly regarding progress and any recommendations for technology improvement
Pg 18
MaRS EXCITE
Methodological CentreCompany
(Technology Innovator)
A B
C
D-X
Participating Centres
EXCITE contract framework
A: Participation Agreement: MaRS and MC B: Participation Agreement: MaRS and Company C: Statement of Work: MC and Company
D-X: Subcontracts: MC and participating centre/sub-contracting MCs.
EXCITE evaluations increase likelihood of adoption and market uptake of disruptive health technology innovations
EXCITE provides access to a vast, coordinated network of world-class medical expertise with experience in real-time evaluation of health technologies
EXCITE’s earlier feedback loop provides insight during formative stage
EXCITE’s single, harmonized pre-market evidence development process helps companies navigate the evidence requirements and accelerate market access
EXCITE’s unique advantages to innovators
Pg 20